Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents

Structure

Volumn 8, Issue 1, 2000, Pages 25-33

  Liu, Shenping ^a   Neidhardt, Edie A ^b   Grossman, Trudy H ^b   Ocain, Tim ^b   Clardy, Jon ^a  

^a Department of Obstetrics Gynecology   (United States)

^b Procept Inc   (United States)

Author keywords

Antiproliferative agents; Brequinar; Crystallography; Dihydroorotate dehydrogenase; Leflunomide; Pyrimidine biosynthesis

Indexed keywords

BREQUINAR; CYSTEINE; DIHYDROOROTATE DEHYDROGENASE; FLAVINE MONONUCLEOTIDE; LEFLUNOMIDE; PYRIMIDINE; SERINE;

ARTICLE; BINDING SITE; COMPLEX FORMATION; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; ENZYME STRUCTURE; HUMAN; PRIORITY JOURNAL; PYRIMIDINE SYNTHESIS; STRUCTURE ANALYSIS;

BACTERIA (MICROORGANISMS);

EID: 0034650342     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-2126(00)00077-0     Document Type: Article

References (35)

1. Jones M.E. Pyrimidine nucleotide biosynthesis in animals: genes, enzymes, and regulation of UMP biosynthesis. Annu. Rev. Biochem. 49:1980;253-279.
2. Fairbanks L.D., Bofill M., Ruckemann K., Simmonds H.A. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. J. Biol. Chem. 270:1995;29682-29689.
3. Ruckemann K., Simmonds H.A.et al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J. Biol. Chem. 273:1998;21682-23691.
4. Williamson R.A., Ruth E.et al. Dihydroorotate dehydrogenase is a high affinity binding protein for A771726 and mediator of a range of biological effects of the immunomodulatory compound. J. Biol. Chem. 270:1995;22467-22472.
5. Chen S.F., Perrella F.W., Behrens D.L., Papp L.M. Inhibition of dihydroorotate dehydrogenase activity by brequinar sodium. Cancer Res. 52:1992;3521-3527.
6. Peters G.J., Nadal J.C., Laurensse E.J., de Kant E., Pinedo H.M. Retention of in vivo antipyrimidine effects of Brequinar sodium (DUP-785; NSC 368390) in murine liver, bone marrow and colon cancer. Cancer Res. 50:1990;4644-4649.
7. Joshi A.S., Kornhauser D.M.et al. Phase I safety and pharmacokinetic studies of brequinar sodium after single ascending oral doses in stable renal, hepatic, and cardiac allograft recipients. J. Clin. Pharmacol. 37:1997;1121-1128.
8. Dimitrijevic M., Bartlett R.R. Leflunomide, a novel immunomodulating drug, inhibits homotypic adhesion of peripheral blood and synovial fluid mononuclear cells in rheumatoid arthritis. Inflamm. Res. 45:1996;550-556.
9. Silva H.T. Jr., Morris R.E. Leflunomide and malononitrilamides. Am. J. Med. Sci. 313:1997;289-301.
10. Smolen J.S., Rosenburg R.et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet. 353:1999;259-266.
11. Bjornberg O., Rowland P., Larsen S., Jensen K.F. Active site of dihydroorotate dehydrogenase A from Lactococcus lactis investigated by chemical modification and mutagenesis. Biochemistry. 36:1997;16197-16205.
12. Nagy M., Lacroute F., Thomas D. Divergent evolution of pyrimidine biosynthesis between anaerobic and aerobic yeasts. Proc. Natl Acad. Sci. USA. 89:1992;8966-8970.
13. Minet M., Dufour M., Lacroute F. Cloning and sequencing of a human cDNA coding for dihydroorotate dehydrogenase by complementation of the corresponding yeast mutant. Gene. 121:1992;393-396.
14. Copeland R.A., Patterson T.A.et al. Recombinant human dihydroorotate dehydrogenase: expression, purification, and characterization of a catalytically functional truncated enzyme. Arch. Biochem. Biophys. 323:1995;79-86.
15. Rowland P., Nielsen F.S., Jensen K.F., Larsen S. The crystal structure of the flavin containing enzyme dihydroorotate dehydrogenase A from Lactococcus lactis. Structure. 5:1997;239-252.
16. Rowland P., Bjornberg O., Nielsen F.S., Jensen K.F., Larsen S. The crystal structure of Lactococcus lactis dihydroorotate dehydrogenase A complexed with the enzyme reaction product throws light on its enzymatic function. Protein Sci. 7:1998;1269-1279.
17. Picot D., Loll P.J., Garavito R.M. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature. 367:1994;243-249.
18. Knecht W., Bergjohann U., Gonski S., Kirschbaum B., Loffler M. Functional expression of a fragment of human dihydroorotate dehydrogenase by means of the baculovirus expression vector system, and kinetic investigation of the purified recombinant enzyme. Eur. J. Biochem. 240:1996;292-301.
19. Davis J., Copeland R.A. Histidine to alanine mutants of human dihydroorotate dehydrogenase. Identification of a brequinar-resistant mutant enzyme. Biochem. Pharmacol. 54:1997;459-465.
20. Bartlett R.R., Bremer E.et al. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents Actions. 32:1991;10-21.
21. Bjornberg O., Gruner A.C., Roepstorff P., Jensen K.F. The activity of Escherichia coli dihydroorotate dehydrogenase is dependent on a conserved loop identified by sequence homology, mutagenesis, and limited proteolysis. Biochemistry. 38:1999;2899-2908.
22. Hines V., Johnston M. Mechanistic studies on the bovine liver mitochondrial dihydroorotate dehydrogenase using kinetic deuterium isotope effects. Biochemistry. 28:1989;1227-1234.
23. Yang Q.H., Wu C.L., Lin K., Li L. Low concentration of inducer favors production of active form of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase in Escherichia coli. Protein Exp. Purif. 10:1997;320-324.
24. Doublie S. Preparation of selenomethionyl proteins for phase determination. Methods Enzymol. 276:1997;523-530.
25. The CCP4 Suite: programs for Protein Crystallography. Acta Crystallogr. D. 50:1994;760-763.
26. Sheldrick G.M. Patterson superposition and ab initio phasing. Methods Enzymol. 276:1997;628-641.
27. Otwinowski Z. Maximum likelihood refinement of heavy atom parameters. Wolf W., Evans P.R., Leslie A.G.W. Isomorphous Replacement and Anomalous scattering. 1991;Daresbury Laboratory, Daresbury, UK.
28. Cowtan K.D., Main P. Miscellaneous algorithms for density modification. Acta Crystallogr. D. 54:1998;487-493.
29. Jones T.A., Zou J.Y., Cowan S.W., Kjeldgaard M. Improved methods for binding protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A. 47:1991;110-119.
30. Brünger A.T., Warren G.L.et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr. D. 54:1998;905-921.
31. Murshudov G.N., Vagin A.A., Lebedev A., Wilson K.S., Dodson E.J. Efficient anisotropic refinement of macromolecular structures using FFT. Acta Crystallogr. D. 55:1999;247-255.
32. Thompson J.D., Higgins D.G., Gibson T.J. CLUSTALW: improving the sensitivity of the progressive multiple sequence alignment through sequence weighting, position specific gap penalties and weight matrix choice. Nucleic Acids Res. 22:1994;4673-4680.
33. Baton G.J. ALSCRIPT: a tool to format multiple sequence alignment. Protein Eng. 6:1993;37-40.
34. Kraulis P.K. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 24:1991;946-950.
35. Nicholls A., Sharp K.A., Honig B. Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins. 11:1991;282.